<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="11.00-Neurological-Adult">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>11.00 Neurological - Adult | Disability | SSA</title>
 
    <!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"false","rua.uprl":"false","rua.cprl":"false","rua.cprf":"false","rua.trans":"","rua.cook":"false","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"false","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="cookiepresent",a="im6jsaqxzhbro2ioay4q-f-889f7f33a-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":20,"ak.ipv":4,"ak.proto":"h3","ak.rid":"ca1743f","ak.r":39734,"ak.a2":n,"ak.m":"dsca","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":57611,"ak.gh":"23.201.194.23","ak.quicv":"0x00000001","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762526777","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==wcqQS+FtyWS+ZE/qI7v/GHigAuXWeIKKWTAS7VeXrqBZxu0jjPQudM4o/ERpj15/psTEgTLdJu1pbvk6Ue/UALdt8vqCFIBHY/xbSXCam70bEo/ZdiJx+3pRLJkABKjqoTW/xV2Mapm144M0GGtRzDQvvvxlXlhHv5TX4h1+/7IDVThl1WO7DrgOd9AadKDtMz82okR+0rnUnHpxpzcRY++eq9QFVB3ZRJIEFDuahWVLQendFRiMcEf/cJke9zaR1ed4EX7b+5SjTmZC05dgNelLDfp0js+NvAuXuHE5HyVsuoQk3OD2oP68HclQjhv8AEdKvqQRDdUjs47IPbtqQD3Ky8R0oTqjjPnEqlwgN7gmxEqf88uN+ihJn5kpP8xrxlRHek0XbyaQA4U8s5jOb9z0Ihiz+SHZiAOl5tJ+rFw=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/11.00-Neurological-Adult.htm"><meta property="og:title" content="11.00 Neurological - Adult | Disability | SSA"><meta property="og:description" content="11.00-Neurological-Adult"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0">Medical/Professional Relations</h2>
       </div>
    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="AdultListings.htm">Listing of Impairments - Adult Listings (Part A)</a></li> 
    <li aria-current="page">11.00 Neurological - Adult</li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

   <h2><span><b> Disability Evaluation Under Social Security<br>
        <br>
        11.00 Neurological - Adult<br>
        &nbsp;</b></span></h2>
        
                            <!--GRID-->
					<div class="grid">

                         <!--FIRST INNER COLUMN-->
					<article class="cell w-100 m-w-20">

<u><b>Section</b></u><br><br>

	 <p align="left"> 
       <a href="#11_01" title=" 11.01 Category of Impairments, Neurological Disorders"> <b>11.01</b><br>
             Category of Impairments, Neurological Disorders</a><br>
              <br>
              <a href="#11_02" title=" 11.02 Epilepsy"> 
             <b>11.02</b><br>
              Epilepsy</a><br>
              <br>
              <a href="#11_03" title=" 11.03 [Reserved]"> 
             <b>11.03</b><br>
              [Reserved]</a><br>  
	 <br>
	   <a href="#11_04" title=" 11.04 Vascular insult to the brain"><b>11.04</b><br>
	     Vascular insult to the brain</a><br>
	   <br>
	   <a href="#11_05" title=" 11.05 Benign brain tumors"><b>11.05</b><br>
	     Benign brain tumors</a><br>
	   <br>
	   <a href="#11_06" title=" 11.06 Parkinsonian syndrome"><b>11.06</b><br>
	     Parkinsonian syndrome</a><br>
	   <br>
	   <a href="#11_07" title=" 11.07 Cerebral palsy"><b>11.07</b><br>
	     Cerebral palsy</a><br>
	   <br>
	   <a href="#11_08" title=" 11.08 Spinal cord disorders"><b>11.08</b><br>
	     Spinal cord disorders</a><br>
	   <br>
	   <a href="#11_09" title=" 11.09 Multiple sclerosis"><b>11.09</b><br>
	     Multiple sclerosis</a><br>
	   <br>
	   <a href="#11_10" title=" 11.10 Amyotrophic lateral sclerosis (ALS)"><b>11.10</b><br>
	     Amyotrophic lateral sclerosis (ALS)</a><br>
	   <br>
	   <a href="#11_11" title=" 11.11 Post-polio syndrome"><b>11.11</b><br>
	     Post-polio syndrome</a><br>
	   <br>
	   <a href="#11_12" title=" 11.12 Myasthenia gravis"><b>11.12</b><br>
	     Myasthenia gravis</a><br>
	   <br>
	   <a href="#11_13" title=" 11.13 Muscular dystrophy"><b>11.13</b><br>
	     Muscular dystrophy</a><br>
	   <br>
  	   <a href="#11_14" title=" 11.14 Peripheral neuropathy"><b>11.14</b><br>
	     Peripheral neuropathy</a><br>
	   <br>
	   <a href="#11_15" title=" 11.14 [Reserved]"><b>11.15</b><br>
	     [Reserved]</a><br>
	   <br>
       <a href="#11_16" title=" 11.14 [Reserved]"><b>11.16</b><br>
	     [Reserved]</a><br>
	   <br>
	   <a href="#11_17" title=" 11.17 Neurodegenerative disorders of the central nervous system, such as Huntington’s disease, Friedreich’s ataxia, and spinocerebellar degeneration"> 
	     <b>11.17</b><br>
	     Neurodegenerative disorders of the central nervous system, such as Huntington’s disease, Friedreich’s ataxia, and spinocerebellar degeneration</a><br>
	   <br>
	   <a href="#11_18" title=" 11.18 Traumatic brain injury"><b>11.18</b><br>
	     Traumatic brain injury</a><br>
	   <br>
	   <a href="#11_19" title=" 11.19 [Reserved]"><b>11.19</b><br>
	     [Reserved]</a><br>
         <br>
	   <a href="#11_20" title=" 11.20 Coma or persistent vegetative state"><b>11.20</b><br>
	     Coma or persistent vegetative state</a><br>
         <br>
       <a href="#11_21" title=" 11.21 [Reserved]"><b>11.21</b><br>
	     [Reserved]</a><br>
         <br>
       <a href="#11_22" title=" 11.22 Motor neuron disorders other than ALS"><b>11.22</b><br>
	     Motor neuron disorders other than ALS</a><br>
         <br>
         
                            </p></article><!--END FIRST INNER COLUMN-->

							<!--SECOND inner COLUMN-->
							<article class="cell w-100 m-w-80">
                            
      <p id="11_00"><u><b>11.00 Neurological</b></u></p>
      <p align="left" id="11_00A">
          A. <u>Which neurological  disorders do we evaluate under these listings?</u>
      </p>
      <p align="left">
          We evaluate epilepsy, amyotrophic lateral sclerosis, coma or persistent vegetative state (PVS), and neurological disorders that cause disorganization of motor function, bulbar and neuromuscular dysfunction, 
          communication impairment, or a combination of  limitations in physical and mental functioning such as early-onset Alzheimer’s  disease. 
          We evaluate neurological disorders that may manifest in a combination of limitations in physical and mental functioning. For example, if you have a neurological disorder that causes mental limitations, 
          such as Huntington’s disease, which may limit executive functioning (e.g., regulating attention, planning, inhibiting responses, decision-making), 
          we evaluate your limitations using the functional criteria under these listings (see <a href="#11_00G" title="Section 11.00, Subsection G">11.00G</a>). Under this body system, 
          we evaluate the limitations resulting from the impact of the  neurological disease process itself. 
          If your neurological disorder results in only mental impairment or if you have a co-occurring mental condition that is not caused by  your neurological disorder (for example, dementia), 
          we will evaluate your  mental impairment under the mental disorders body system, <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.


    <!--Epilepsy<i>. </i>In epilepsy, regardless
      of etiology, degree of impairment will be determined according to
      type, frequency, duration, and sequelae of seizures. At least one
      detailed description of a typical seizure is required. Such description
      includes the presence or absence of aura, tongue bites, sphincter
      control, injuries associated with the attack, and postictal phenomena.
      The reporting physician should indicate the extent to which description
      of seizures reflects his own observations and the source of ancillary
      information. Testimony of persons other than the claimant is essential
      for description of type and frequency of seizures if professional
      observation is not available. </p>
    <p align="left"> Under 11.02 and 11.03,
      the criteria can be applied only if the impairment persists despite
      the fact that the individual is following prescribed antiepileptic
      treatment. Adherence to prescribed antiepileptic therapy can ordinarily
      be determined from objective clinical findings in the report of
      the physician currently providing treatment for epilepsy. Determination
      of blood levels of phenytoin sodium or other antiepileptic drugs
      may serve to indicate whether the prescribed medication is being
      taken. When seizures are occurring at the frequency stated in 11.02
      or 11.03, evaluation of the severity of the impairment must include
      consideration of the serum drug levels. <br>
      <br>
      Should serum drug levels appear therapeutically inadequate, consideration
      should be given as to whether this is caused by individual idiosyncrasy
      in absorption or metabolism of the drug. Blood drug levels should
      be evaluated in conjunction with all other evidence to determine
      the extent of compliance. When the reported blood drug levels are
      low, therefore, the information obtained from the treating source
      should include the physician's statement as to why the levels are
      low and the results of any relevant diagnostic studies concerning
      the blood levels. Where adequate seizure control is obtained only
      with unusually large doses, the possibility of impairment resulting
      from the side effects of this medication must also be assessed.
      Where documentation shows that use of alcohol or drugs affects adherence
      to prescribed therapy or may play a part in the precipitation of
      seizures, this must also be considered in the overall assessment
      of impairment level. -->
</p>
      <p align="left" id="11_00B">B. <u>What evidence do we need to document your neurological disorder?</u></p>
      <ol type="1">
          <li id="11_00B1">We need both medical and non-medical evidence (signs, symptoms, and laboratory findings) to assess  the effects of your neurological disorder. Medical evidence should include your  medical history, examination findings, relevant laboratory tests, and the  results of imaging. Imaging refers to medical imaging techniques, such as  x-ray, computerized tomography (CT), magnetic resonance imaging (MRI), and  electroencephalography (EEG). The imaging must be consistent with the  prevailing state of medical knowledge and clinical practice as the proper  technique to support the evaluation of the disorder. In addition, the medical  evidence may include descriptions of any prescribed treatment and your response  to it. We consider non-medical evidence such as statements you or others make  about your impairments, your restrictions, your daily activities, or your  efforts to work. </li>
          <li id="11_00B2">
              We will make every reasonable effort to obtain the results of your laboratory and imaging evidence. When the results of any of these tests are part of the existing evidence in your case record, we will evaluate the test results and all other relevant evidence. We will not  purchase imaging, or other diagnostic tests, or laboratory tests that are complex, may involve significant risk, or that  are invasive. We will not routinely purchase tests that are expensive or not  readily available. 
          </li>
      </ol>

      <p id="11_00C">C. <u>How do we consider  adherence to prescribed treatment in neurological disorders?</u></p>
      <p>In <a href="#11_02" title="Section 11.02">11.02</a> (Epilepsy), <a href="#11_06" title="Section 11.06">11.06</a> (Parkinsonian  syndrome), 
      and <a href="#11_12" title="Section 11.12">11.12</a> (Myasthenia gravis), we require that limitations from  these neurological disorders exist despite adherence to prescribed treatment.  
      “Despite adherence to prescribed treatment” means that you have taken medication(s) or followed other treatment procedures for your neurological disorder(s) 
      as prescribed by a physician for three consecutive months but your impairment  continues to meet the other listing requirements despite this treatment. 
      You  may receive your treatment at a health care facility that you visit regularly, even if you do not see the same physician on each visit. </p>
      <p align="left" id="11_00D">D. <u>What do we mean by disorganization of motor function?</u></p>
          <ol type="1">
              <li id="11_00D1">
                  <u>Disorganization of motor function</u> means interference, due to your neurological disorder, with movement of two extremities; i.e., the lower extremities, or upper extremities 
                    (including fingers, wrists, hands, arms, and shoulders). By two  extremities we mean both lower extremities, or both upper extremities, or one  upper extremity and one lower extremity. 
                    All listings in this body system,  except for <a href="#11_02" title="Section 11.02">11.02</a> (Epilepsy), <a href="#11_10" title="Section 11.10">11.10</a> (Amyotrophic lateral sclerosis), 
                    and <a href="#11_20" title="Section 11.20">11.20</a> (Coma and persistent vegetative state), include criteria for disorganization of motor function that results in an extreme limitation in your ability to:
    <ul style="list-style-type:square">
        <li>Stand up from a seated position; or</li>
        <li>Balance while standing or walking; or </li>
        <li>
            Use the upper extremities (including fingers, wrists, hands, arms, and shoulders).<br>
            <br>
        </li>
    </ul>
</li>
              <li id="11_00D2">
                  <u>Extreme limitation</u> means the inability to stand up from a seated position, maintain balance in a  standing position and while walking, or use your upper extremities to  independently initiate, sustain, and complete work-related activities. The  assessment of motor function depends on the degree of interference with standing  up; balancing while standing or walking; or using the upper extremities  (including fingers, hands, arms, and shoulders).
                  <ol type="a">
                      <li id="11_00D2a">Inability to stand up from a seated position means that once seated you are unable to stand and maintain an upright position without the assistance of another person or the  use of an assistive device, such as a walker, two crutches, or two canes. </li>
                      <li id="11_00D2b">Inability to maintain balance in a standing position means that you are unable to maintain an upright position while standing or walking without the assistance of another person or  an assistive device, such as a walker, two crutches, or two canes. </li>
                      <li id="11_00D2c">Inability to use your upper extremities means that you have a loss of function of both upper extremities (including fingers, wrists, hands, arms, and shoulders) that very seriously limits your ability to independently initiate, sustain, and complete  work-related activities involving fine and gross motor movements. Inability to  perform fine and gross motor movements could include not being able to pinch,  manipulate, and use your fingers; or not being able to use your hands, arms,  and shoulders to perform gross motor movements, such as handling, gripping,  grasping, holding, turning, and reaching; or not being able to engage in  exertional movements such a lifting, carrying, pushing, and pulling.</li>
                  </ol>
              </li>
            </ol>
      <p align="left" id="11_00E">
          E. <u>How do we evaluate communication impairments under these listings?</u> We must have a description of a recent comprehensive evaluation including all areas of communication, performed by an acceptable medical source, 
            to document a communication impairment associated  with a neurological disorder. 
            A communication impairment may occur when a medically determinable neurological impairment results in dysfunction in the  parts of the brain responsible for speech and language. 
            We evaluate communication impairments associated with neurological disorders under <a href="#11_04A" title="Section 11.04, Subsection A">11.04A</a>,  <a href="#11_07C" title="Section 11.07, Subsection C">11.07C</a>, 
            or <a href="#11_11B" title="Section 11.11, Subsection B">11.11B</a>. 
            We evaluate communication impairments due to  non-neurological disorders under <a href="2.00-SpecialSensesandSpeech-Adult.htm#2_09" title="2.00 Special Senses and Speech Page, Section 2.09" target="_blank">2.09</a>.
</p>
          <ol type="1">
              <li id="11_00E1">
                Under <a href="#11_04A" title="Section 11.04, Subsection A">11.04A</a>, we need evidence documenting that your central nervous system vascular accident or insult (CVA) 
                  and sensory or motor aphasia have resulted in ineffective speech or communication. 
                  <u>Ineffective speech or communication</u> means there is an extreme limitation in your ability to understand or convey your message in simple spoken language resulting in your inability to demonstrate basic 
                  communication skills, such as following one-step commands or telling someone about your basic personal needs without assistance.
              </li>
              <li id="11_00E2">
                  Under <a href="#11_07C" title="Section 11.07, Subsection C">11.07C</a>, we need evidence documenting that your cerebral palsy has resulted in significant interference in your ability to speak, hear, or see. 
                  We will find  you have “significant interference” in your ability to speak, hear, or see if  your signs, such as aphasia, strabismus, or sensorineural hearing loss, 
                  seriously limit your ability to communicate on a sustained basis.
              </li>
              <li id="11_00E3">
                  Under <a href="#11_11B" title="Section 11.11, Subsection B">11.11B</a>, we need evidence documenting that your post-polio syndrome has resulted in the inability to produce intelligible speech.
              </li>
        </ol>
      <!--Multiple sclerosis. The major criteria for evaluating impairment caused by multiple
                  sclerosis are discussed in Listing 11.09. Paragraph A provides criteria
                  for evaluating disorganization of motor function and gives reference
                  to 11.04B (11.04B then refers to 11.00C). Paragraph B provides references
                  to other listings for evaluating visual or mental impairments caused
                  by multiple sclerosis. Paragraph C provides criteria for evaluating
                  the impairment of individuals who do not have muscle weakness or
                  other significant disorganization of motor function at rest, but
                  who do develop muscle weakness on activity as a result of fatigue.
                 </p>
                <p align="left"> Use of the criteria in
                  11.09C is dependent upon (1) documenting a diagnosis of multiple
                  sclerosis, (2) obtaining a description of fatigue considered to
                  be characteristic of multiple sclerosis, and (3) obtaining evidence
                  that the system has actually become fatigued. The evaluation of
                  the magnitude of the impairment must consider the degree of exercise
                  and the severity of the resulting muscle weakness. </p>
                <p align="left"> The criteria in 11.09C
                  deal with motor abnormalities which occur on activity. If the disorganization
                  of motor function is present at rest, paragraph A must be used,
                  taking into account any further increase in muscle weakness resulting
                  from activity.</p>
                <p align="left"> Sensory abnormalities
                  may occur, particularly involving central visual acuity. The decrease
                  in visual acuity may occur after brief attempts at activity involving
                  near vision, such as reading. This decrease in visual acuity may
                  not persist when the specific activity is terminated, as with rest,
                  but is predictably reproduced with resumption of the activity. The
                  impairment of central visual acuity in these cases should be evaluated
                  under the criteria in Listing 2.02, taking into account the fact
                  that the decrease in visual acuity will wax and wane. </p>
                <p align="left"> Clarification of the
                  evidence regarding central nervous system dysfunction responsible
                  for the symptoms may require supporting technical evidence of functional
                  impairment such as evoked response tests during exercise.<br>
                   &nbsp;</p> -->

      <p align="left" id="11_00F">F. <u>What do we mean by bulbar and neuromuscular dysfunction?</u> The bulbar region of the brain is responsible for controlling the bulbar muscles in the throat, tongue, 
      jaw, and face. Bulbar and neuromuscular dysfunction refers to weakness in these muscles, resulting in breathing, swallowing, and speaking impairments. 
    Listings <a href="#11_11" title="Section 11.11">11.11</a> (Post-polio syndrome),  <a href="#11_12" title="Section 11.12">11.12</a> (Myasthenia gravis), 
      and <a href="#11_22" title="Section 11.22">11.22</a> (Motor neuron disorders other than ALS) include criteria for evaluating bulbar and neuromuscular dysfunction. 
      If your neurological disorder has resulted in a breathing disorder, we may evaluate  that condition under the respiratory system, 
          <a href="3.00-Respiratory-Adult.htm#3_00" title="3.00 Respiratory Disorders Page, Section 3.00" target="_blank">3.00</a>.</p>

      <p id="11_00G">G. <u>How do we evaluate limitations in physical and mental functioning under these listings?</u></p>
      <ol type="1">
          <li id="11_00G1">
              Neurological disorders may manifest in a combination of limitations in physical and mental functioning.
              We consider all relevant information in your case record to determine the effects of your neurological disorder on your physical and mental functioning.
              To satisfy the requirement described under 11.00G, your neurological  disorder must result in a marked limitation in physical functioning and a  marked limitation in at least one of four areas of mental functioning:
              understanding, remembering, or applying information; interacting with others;  concentrating, persisting, or maintaining pace; or adapting or managing oneself.
              If your neurological disorder results in an extreme limitation in at least one of the four areas of mental functioning, or results in marked limitation in at least two of the four areas of mental functioning,
              but you do  not have at least a marked limitation in your physical functioning, we will  consider whether your condition meets or medically equals one of the mental disorders body system listings,
              <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.
          </li>

          <li id="11_00G2"><u>Marked Limitation</u>. To satisfy the requirements of the functional criteria, 
          your neurological disorder must result in a marked limitation in physical functioning and a marked limitation in one of the four areas of mental functioning 
          (see <a href="#11_00G3" title="Section 11.00, Subsection G3">11.00G3</a>). Although  we do not require the use of such a scale, "marked" would be the  fourth point on a five-point scale consisting of no limitation, mild limitation, moderate limitation,
    marked limitation, and extreme limitation. We  consider the nature and overall degree of interference with your functioning.
    The term "marked" does not require that you must be confined to bed, hospitalized, or in a nursing home.
</li>
          <ol type="a">
              <li id="11_00G2a">
                  <u>Marked limitation and physical functioning</u>. For this criterion, a marked limitation means that, due to the signs and symptoms of your neurological disorder, 
                you are seriously limited in the ability to independently initiate, sustain, and complete work-related physical activities (see <a href="#11_00G3" title="Section 11.00, Subsection G3">11.00G3</a>).
    You may have a marked limitation in your physical  functioning when your neurological disease process causes persistent or  intermittent symptoms that affect your abilities to independently initiate,  sustain, and complete work-related activities, such as standing, balancing,  walking, using both upper extremities for fine and gross movements, or results  in limitations in using one upper and one lower extremity. The persistent and  intermittent symptoms must result in a serious limitation in your ability to do  a task or activity on a sustained basis. We do not define "marked" by a specific number of different  physical activities or tasks that demonstrate your ability, but by the overall  effects of your neurological symptoms on your ability to perform such physical  activities on a consistent and sustained basis. You need not be totally  precluded from performing a function or activity to have a marked limitation,  as long as the degree of limitation seriously limits your ability to  independently initiate, sustain, and complete work-related physical activities.
</li>
              <li id="11_00G2b"><u>Marked limitation and mental functioning</u>.  For this criterion, a marked limitation means that, due to the signs and symptoms of your neurological disorder, 
              you are seriously limited in the ability to function  independently, appropriately, effectively, 
              and on a sustained basis in work settings (see <a href="#11_00G3" title="Section 11.00, Subsection G3">11.03G3</a>). We do  not define “marked” by a specific number of mental activities, such as: the  number of activities that demonstrate your ability to understand, remember, and  apply information; the number of tasks that demonstrate your ability to  interact with others; a specific number of tasks that demonstrate you are able  to concentrate, persist or maintain pace; or a specific number of tasks that  demonstrate you are able to manage yourself. You may have a marked limitation  in your mental functioning when several activities or functions are impaired,  or even when only one is impaired. You need not be totally precluded from  performing an activity to have a marked limitation, as long as the degree of  limitation seriously limits your ability to function independently,  appropriately, and effectively on a sustained basis, and complete work-related  mental activities. </li>
          </ol>

          <li id="11_00G3"><u>Areas of physical and mental functioning.</u></li>
          <ol type="a">
              <li id="11_00G3a"><u>Physical functioning</u>. Examples of this criterion include specific motor abilities, such as independently initiating, sustaining, and completing the following activities: 
              standing up from a seated position, balancing while standing or walking, 
              or using both your upper extremities for fine and gross movements (see <a href="#11_00D" title="Section 11.00, Subsection D">11.00D</a>). 
              Physical functioning may also include functions of the body that support motor abilities, such as the abilities to see, breathe, 
              and swallow (see <a href="#11_00E" title="Section 11.00, Subsection E">11.00E</a> and <a href="#11_00F" title="Section 11.00, Subsection F">11.00F</a>). 
              Examples of when your limitation in seeing, breathing, or swallowing may, on its own, rise to a “marked” limitation  include: prolonged and uncorrectable double vision causing difficulty with  balance; 
              prolonged difficulty breathing requiring the use of a prescribed assistive breathing device, such as a portable continuous positive airway pressure machine; or repeated instances, occurring at least weekly, 
              of aspiration without causing aspiration pneumonia. Alternatively, you may have a combination of limitations due to your neurological disorder that together rise to a “marked” limitation in physical functioning. 
              We may also find that you have a “marked” limitation in this area if, for example, your symptoms, such as pain or fatigue 
              (see <a href="#11_00T" title="Section 11.00, Subsection T">11.00T</a>), as documented in your medical record, and caused by your  neurological disorder or its treatment, 
              seriously limit your ability to independently initiate, sustain, and complete these work-related motor functions, or the other physical functions or physiological processes that support those motor functions. 
              We may also find you seriously limited in an area if, while you retain some ability to perform the function, you are unable to do so consistently and  on a sustained basis. 
              The limitation in your physical functioning must last or be expected to last at least 12 months. These examples illustrate the nature of physical functioning. We do not require documentation of all of the examples.
</li>
              <li id="11_00G3b">
                  <u>Mental functioning.</u>
                  <ol type="i">
                      <li id="11_00G3bi">
                          <u>Understanding, remembering, or applying information.</u> This area of mental functioning refers to the abilities  to learn, recall, and use information to perform work activities. Examples include: understanding and learning terms, instructions, procedures; following  one- or two-step oral instructions to carry out a task; describing work  activity to someone else; asking and answering questions and providing  explanations; recognizing a mistake and correcting it; identifying and solving  problems; sequencing multi-step activities; and using reason and judgment to  make work-related decisions. These examples illustrate the nature of this area  of mental functioning. We do not require documentation of all of the examples.
                      </li>
                      <li id="11_00G3bii">
                          <u>Interacting with others.</u> This area of mental functioning refers to the abilities to relate to and work with supervisors, co-workers, and the public. Examples include: cooperating with others; asking  for help when needed; handling conflicts with others; stating your own point of  view; initiating or sustaining conversation; understanding and responding to  social cues (physical, verbal, emotional); responding to requests, suggestions,  criticism, correction, and challenges; and keeping social interactions free of  excessive irritability, sensitivity, argumentativeness, or suspiciousness.  These examples illustrate the nature of this area of mental functioning. We do  not require documentation of all of the examples.
                      </li>
                      <li id="11_00G3biii">
                          <u>Concentrating, persisting, or maintaining pace.</u> This area of mental  functioning refers to the abilities to focus attention on work activities and to stay on-task at a sustained rate. Examples include: initiating and  performing a task that you understand and know how to do; working at an appropriate  and consistent pace; completing tasks in a timely manner; ignoring or avoiding  distractions while working; changing activities or work settings without being  disruptive; working close to or with others without interrupting or distracting  them; sustaining an ordinary routine and regular attendance at work; and  working a full day without needing more than the allotted number or length of  rest periods during the day. These examples illustrate the nature of this area  of mental functioning. We do not require documentation of all of the examples.
                      </li>
                      <li id="11_00G3biv">
                          <u>Adapting or  managing oneself.</u> This area of mental functioning refers to the abilities to&nbsp; regulate emotions, control behavior, and maintain well-being in a work  setting. Examples include: responding  to demands; adapting to changes; managing your psychologically based symptoms;  distinguishing between acceptable and unacceptable work performance; setting  realistic goals; making plans for yourself independently of others; maintaining  personal hygiene and attire appropriate to a work setting; and being aware of  normal hazards and taking appropriate precautions. These examples  illustrate the nature of this area of mental functioning. We do not require  documentation of all of the examples.
                      </li>
                  </ol>
              </li>
          </ol>

          <li id="11_00G4"><u>Signs and symptoms of your disorder and the effects of treatment.</u></li>
          <ol type="a">
              <li id="11_00G4a">We will consider your signs and symptoms and how they affect your ability to function in the work place. When we evaluate your functioning, we will consider whether your signs and symptoms are persistent or intermittent, how frequently they occur and how long they last, their intensity, and whether you have periods of exacerbation and remission.</li>
              <li id="11_00G4b">We will consider the effectiveness of treatment in improving the signs, symptoms, and laboratory findings related to your neurological disorder, as well as any aspects of  treatment that may interfere with your ability to function. We will consider,  for example: the effects of medications you take (including side effects); the  time-limited efficacy of some medications; the intrusiveness, complexity, and  duration of your treatment (for example, the dosing schedule or need for  injections); the effects of treatment, including medications, therapy, and  surgery, on your functioning; the variability of your response to treatment;  and any drug interactions. </li>
          </ol>
      </ol>
      <p id="11_00H">H. <u>What is epilepsy, and how do we evaluate it under <a href="#11_02" title="Section 11.02">11.02</a>? </u></p>
      <ol type="1">
          <li id="11_00H1">
              <u>Epilepsy</u> is a pattern of recurrent and unprovoked seizures that are manifestations of  abnormal electrical activity in the brain. There are various types of generalized and “focal” or partial seizures. 
            However, psychogenic nonepileptic seizures and pseudoseizures are not epileptic seizures for the purpose of <a href="#11_02" title="Section 11.02">11.02</a>. 
          We evaluate psychogenic seizures and pseudoseizures under the mental disorders body system,  <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>. 
          In adults, the most common potentially disabling seizure types are <u>generalized tonic-clonic seizures</u> and <u>dyscognitive seizures </u>(formerly complex partial seizures).
</li>
          <ol type="a">
              <li id="11_00H1a">
                    <u>Generalized tonic-clonic seizures</u> are characterized by loss of consciousness accompanied by a tonic phase (sudden muscle tensing causing the person to lose postural control) followed by a clonic phase (rapid cycles of muscle  contraction and relaxation, also called convulsions). Tongue biting and  incontinence may occur during generalized tonic-clonic seizures, and injuries  may result from falling.
              </li>
              <li id="11_00H1b">
                  <u>Dyscognitive seizures</u> are characterized by alteration of consciousness without convulsions or loss of muscle control. During the seizure, blank staring, change of facial expression, 
                    and automatisms (such as lip smacking,  chewing or swallowing, or repetitive simple actions, such as gestures or verbal  utterances) may occur. During its course, 
                    a dyscognitive seizure may progress into a generalized tonic-clonic seizure (see <a href="#11_00H1a" title="Section 11.00, Subsection H1a">11.00H1a</a>).
</li>
          </ol>
          <li id="11_00H2">
              <u>Description of seizure.</u> We require at least one detailed description of your seizures from someone, preferably a medical professional, who has observed at least one of your typical seizures. If you  experience more than one type of seizure, we require a description of each  type.
          </li>
          <li id="11_00H3"><u>Serum drug levels.</u> We do not require serum drug levels; therefore,  we will not purchase them. However, if serum drug levels are available in your  medical records, we will evaluate them in the context of the other evidence in  your case record. </li>
          <li id="11_00H4">
              <u>Counting seizures.</u> The period specified in <a href="#11_02A" title="Section 11.02, Subsection A">11.02A</a>, <a href="#11_02B" title="Section 11.02, Subsection B">B</a>, 
          or <a href="#11_02C" title="Section 11.02, Subsection C">C</a> cannot begin earlier than one month after you began prescribed treatment.
    The required number of seizures must occur within the period we are considering in connection with your application or continuing disability review. When we evaluate the frequency of your seizures,
    we also consider your adherence to  prescribed treatment (see <a href="#11_00C" title="Section 11.00, Subsection C">11.00C</a>). When we determine the number of seizures you  have had in the specified period, we will:
</li>
          <ol type="a">
              <li id="11_00H4a">
                  Count multiple seizures occurring in a 24-hour period as one seizure.
              </li>
              <li id="11_00H4b">Count status epilepticus (a continuous series of seizures without return to consciousness  between seizures) as one seizure. </li>
              <li id="11_00H4c">Count a dyscognitive  seizure that progresses into a generalized tonic-clonic seizure as one  generalized tonic-clonic seizure. </li>
              <li id="11_00H4d">We do not count seizures that occur during a period when you are not adhering to prescribed treatment without good reason.  
              When we determine that you had good reason for not adhering to prescribed  treatment, we will consider your physical, mental, educational, and communicative limitations (including any language barriers). 
              We will consider you to have good reason for not following prescribed treatment if, for example, the treatment is very risky for you due to its consequences or unusual nature, 
              or if you are unable to afford prescribed treatment that you are willing to accept, but for which no free community resources are available. 
              We will follow  guidelines found in our policy, such as §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1530.htm#c" target="_blank" title="Code of Federal Regulations section 404.1530, Subsection C">404.1530(c)</a>
    and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0930.htm#c" target="_blank" title="Code of Federal Regulations section 416.930, Subsection c">416.930(c)</a> of this chapter,
    when we determine whether you have a good reason for not adhering to prescribed treatment.
</li>
              <li id="11_00H4e">We do not count psychogenic nonepileptic seizures or pseudoseizures under <a href="#11_02" title="Section 11.02">11.02</a>. 
              We evaluate these seizures under the mental disorders body system, <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.</li>
          </ol>
          <li id="11_00H5"><u>Electroencephalography (EEG) testing.</u> We do not require EEG test results; therefore, we will not purchase them. However, if EEG test results are available in your medical records, we will evaluate them in the  context of the other evidence in your case record. </li>
      </ol>
      <p id="11_00I">I. <u>What is vascular insult to the brain, and how do we evaluate it under <a href="#11_04" title="Section 11.04">11.04</a>?</u></p>
      <ol type="1">
          <li id="11_00I1"><u>Vascular insult to the brain</u> (cerebrum, cerebellum, or  brainstem), commonly referred to as stroke or cerebrovascular accident (CVA), 
          is brain cell death caused by an interruption of blood flow within or leading  to the brain, or by a hemorrhage from a ruptured blood vessel or aneurysm in the brain. 
          If you have a vision impairment resulting from your vascular insult, we may evaluate that impairment  under the special senses body system, 
          <a href="2.00-SpecialSensesandSpeech-Adult.htm#2_00" title="2.00 Special Senses and Speech Page, Section 2.00" target="_blank">2.00</a>.</li>
          <li id="11_00I2">We need evidence of sensory or motor aphasia that results in ineffective speech or communication under <a href="#11_04A" title="Section 11.04, Subsection A">11.04A</a> 
          (see <a href="#11_00E" title="Section 11.00, Subsection E">11.00E</a>).
    We may evaluate your communication impairment under listing <a href="#11_04C" title="Section 11.04, Subsection C">11.04C</a> if you have marked limitation in physical functioning and marked limitation in one of the four areas of mental functioning.&nbsp;
</li>
          <li id="11_00I3">We generally need evidence from at least 3 months after the vascular insult to evaluate whether you have disorganization of motor functioning under 
          <a href="#11_04B" title="Section 11.04, Subsection B">11.04B</a>, 
          or the impact that your disorder has on your physical and mental functioning under <a href="#11_04C" title="Section 11.04, Subsection C">11.04C</a>. 
          In some cases, evidence of your vascular insult is sufficient to allow your claim within 3 months post-vascular insult. If we are unable to allow your claim within 3 months after your vascular insult, 
          we will defer adjudication of the claim until we obtain evidence of your neurological disorder at least 3 months post-vascular insult. </li>
      </ol>
      <p id="11_00J">
          J. <u>What are benign  brain tumors, and how do we evaluate them under <a href="#11_05" title="Section 11.05">11.05</a>?</u> 
          Benign brain tumors are noncancerous (nonmalignant) abnormal growths of tissue in or on the brain  that invade healthy brain tissue or apply pressure on the brain or cranial nerves. 
          We evaluate their effects on your functioning as discussed in <a href="#11_00D" title="Section 11.00, Subsection D">11.00D</a> and 
          <a href="#11_00G" title="Section 11.00, Subsection G">11.00G</a>.
          We evaluate malignant brain tumors under the cancer body system in <a href="13.00-NeoplasticDiseases-Malignant-Adult.htm#13_00" title="13.00 Cancer (Malignant Neoplastic Diseases) Page" target="_blank">13.00</a>.
    If you have a vision impairment resulting from your benign brain tumor, we may evaluate that impairment under the special senses body system,
    <a href="2.00-SpecialSensesandSpeech-Adult.htm#2_00" title="2.00 Special Senses and Speech Page, Section 2.00" target="_blank">2.00</a>.
</p>
      <p id="11_00K">K. <u>What is Parkinsonian syndrome, and how do we evaluate it under <a href="#11_06" title="Section 11.06">11.06</a>?</u> 
      Parkinsonian syndrome is a term that describes a group of chronic, progressive  movement disorders resulting from loss or decline in the function of dopamine-producing brain cells. 
      Dopamine is a neurotransmitter that regulates  muscle movement throughout the body. When we evaluate your Parkinsonian syndrome, 
      we will consider your adherence to prescribed treatment (see <a href="#11_00C" title="Section 11.00, Subsection C">11.00C</a>).</p>
      <p id="11_00L">L. <u>What is cerebral palsy, and how do we evaluate it under <a href="#11_07" title="Section 11.07">11.07</a>?</u></p>
      <ol type="1">
          <li id="11_00L1"><u>Cerebral palsy (CP)</u> is a term that describes a group of static, 
          nonprogressive disorders caused by abnormalities within the brain that disrupt the brain's ability to control movement, muscle coordination, and posture. 
          The resulting motor deficits manifest very early in a person’s development, with delayed or abnormal progress in attaining developmental milestones. 
          Deficits may become more obvious as the person grows and matures over time.</li>
          <li id="11_00L2">We evaluate your signs and symptoms, such as ataxia, spasticity, flaccidity, athetosis, chorea,  and difficulty with precise movements when we determine your ability to stand  up, balance, walk, or perform fine and gross motor movements. We will also  evaluate your signs, such as dysarthria and apraxia of speech, and receptive and  expressive language problems when we determine your ability to communicate. </li>
          <li id="11_00L3">We will consider your other impairments or signs and symptoms that develop  secondary to the disorder, such as post-impairment syndrome (a combination of  pain, fatigue, and weakness due to muscle abnormalities); overuse syndromes  (repetitive motion injuries); arthritis; abnormalities of proprioception  (perception of the movements and position of the body); abnormalities of  stereognosis (perception and identification of objects by touch); learning  problems; anxiety; and depression.</li>
      </ol>
      <p id="11_00M">M. <u>What are spinal cord disorders, and how do we evaluate them under <a href="#11_08" title="Section 11.08">11.08</a>?</u></p>
      <ol type="1">
          <li id="11_00M1"><u>Spinal cord disorders</u> may be congenital or caused by injury to the  spinal cord. Motor signs and symptoms of spinal cord disorders include paralysis, flaccidity, spasticity, 
          and weakness.</li>
          <li id="11_00M2"><u>Spinal cord disorders with complete loss of function</u> (<a href="#11_08A" title="Section 11.08, Subsection A">11.08A</a>) addresses spinal cord disorders that result in a complete lack of motor, sensory,
    and autonomic function of the affected part(s) of the body.
</li>
          <li id="11_00M3"><u>Spinal cord disorders with disorganization of motor function </u>(<a href="#11_08B" title="Section 11.08, Subsection B">11.08B</a>) 
          addresses spinal cord disorders that result in less than a  complete loss of function of the affected part(s) of the body, reducing, but not eliminating, motor, sensory, and autonomic function. </li>
          <li id="11_00M4">When we evaluate your spinal cord disorder, we generally need evidence from at least 3 months after your symptoms began in order to evaluate your disorganization of motor function. 
          In some cases, evidence of your spinal cord disorder may be sufficient to allow your claim within 3 months after the spinal cord disorder. 
          If the medical evidence demonstrates total cord transection causing a loss of motor and sensory functions below the level of injury, we will not wait 3 months but will make the allowance decision immediately.</li>
      </ol>
      <p id="11_00N">N. <u>What is multiple sclerosis, and how do we evaluate it under <a href="#11_09" title="Section 11.09">11.09</a>?</u> <u> </u></p>
      <ol type="1">
          <li id="11_00N1"><u>Multiple sclerosis (MS)</u> is a chronic, inflammatory, degenerative  disorder that damages the myelin sheath surrounding the nerve fibers in the  brain and spinal cord. 
          The damage disrupts the normal transmission of nerve impulses within  the brain and between the brain and other parts of the body, causing impairment  in muscle coordination, strength, balance, sensation, and vision. 
          There are  several forms of MS, ranging from mildly to highly aggressive. Milder forms  generally involve acute attacks (exacerbations) with partial or complete  recovery from signs and symptoms (remissions). 
          Aggressive forms generally  exhibit a steady progression of signs and symptoms with few or no remissions.  The effects of all forms vary from person to person. </li>
          <li id="11_00N2">We evaluate your signs and symptoms, such as flaccidity, spasticity, spasms, incoordination, imbalance, tremor, physical fatigue, muscle weakness, dizziness, tingling, 
          and numbness when we determine your ability to stand up, balance, walk, or perform  fine and gross motor movements. When determining whether you have limitations of physical and mental functioning, 
          we will consider your other impairments or signs and symptoms that develop secondary to the disorder, such as fatigue; visual loss; trouble sleeping; impaired attention, concentration, memory, or judgment; mood swings; 
          and depression. If you have a vision impairment resulting from your MS, we may evaluate that impairment under the special senses body system, <a href="2.00-SpecialSensesandSpeech-Adult.htm#2_00" title="2.00 Special Senses and Speech Page, Section 2.00" target="_blank">2.00</a>.</li>
      </ol>
      <p id="11_00O">O. <u>What is amyotrophic lateral sclerosis, and how do we evaluate it under <a href="#11_10" title="Section 11.10">11.10</a>?</u> 
      <u>Amyotrophic lateral sclerosis (ALS)</u> is a type of motor neuron disorder that rapidly and progressively attacks the  nerve cells responsible for controlling voluntary muscles. We establish ALS under 
      <a href="#11_10" title="Section 11.10">11.10</a> when you have a documented diagnosis of ALS. 
      We require documentation based on generally accepted methods consistent with the prevailing state of medical knowledge and clinical practice.
      We require laboratory testing to establish the diagnosis when the clinical findings of  upper and lower motor neuron disease are not present in three or more regions.  
      Electrophysiological studies, such as nerve conduction velocity studies and electromyography (EMG), may support your diagnosis of ALS; however, we will  not purchase these studies. </p>
      <p id="11_00P">P. <u>What are neurodegenerative disorders of the central nervous system, such as Huntington’s disease, Friedreich’s ataxia, and spinocerebellar degeneration, 
          and how do we evaluate them under <a href="#11_17" title="Section 11.17">11.17</a>?</u> 
        Neurodegenerative disorders of the central nervous system are disorders characterized by progressive and irreversible degeneration of neurons or their supporting cells. 
      Over time, these disorders impair many of the body's motor, cognitive, and other mental  functions. 
      We consider neurodegenerative disorders of the central nervous system under <a href="#11_17" title="Section 11.17">11.17</a> that we do not evaluate elsewhere in section 
      <a href="#11_00" title="Section 11.00">11.00</a>, such as Huntington’s disease (HD), Friedreich’s ataxia, spinocerebellar degeneration, Creutzfeldt-Jakob disease (CJD), progressive supranuclear palsy (PSP), 
      early-onset Alzheimer’s disease, and frontotemporal dementia (Pick’s disease).  When these disorders result in solely cognitive and other mental function effects, 
      we will evaluate the disorder under the mental disorder listings. </p>
      <p id="11_00Q">Q. <u>What is traumatic brain injury, and how do we evaluate it under <a href="#11_18" title="Section 11.18">11.18</a>? </u></p>
      <ol type="1">
          <li id="11_00Q1"><u>Traumatic brain injury (TBI)</u> is damage to the  brain resulting from skull fracture, collision with an external force leading  to a closed head injury, 
          or penetration by an object that enters the skull and  makes contact with brain tissue. 
          We evaluate TBI that results in coma or persistent vegetative state (PVS) under <a href="#11_20" title="Section 11.20">11.20</a>. </li>
          <li id="11_00Q2">We generally need evidence from at least 3 months after the TBI to evaluate whether you have disorganization of motor function under 
              <a href="#11_18A" title="Section 11.18, Subsection A">11.18A</a> or the impact that your disorder has on your physical and mental functioning under 
              <a href="#11_18B" title="Section 11.18B">11.18B</a>. In some cases, evidence of your TBI is sufficient to determine disability within 3 months post-TBI. 
          If we are unable to allow your claim within 3 months post-TBI, we  will defer adjudication of the claim until we obtain evidence of your  neurological disorder at least 3 months post-TBI. If a finding of disability  still is not possible at that time, we will again defer adjudication of the  claim until we obtain evidence at least 6 months after your TBI. </li>
      </ol>
      <p id="11_00R">R. <u>What are coma and persistent vegetative state, and how do we evaluate them under <a href="#11_20" title="Section 11.20">11.20</a>?</u> 
      Coma is a state of unconsciousness in which a person does not  exhibit a sleep/wake cycle, and is unable to perceive or respond to external stimuli. 
      People who do not fully emerge from coma may progress into a persistent vegetative state (PVS). 
      PVS is a condition of partial arousal in which a person may have a low level of consciousness but is still unable to react to external stimuli. 
      In contrast to coma, a person in a PVS retains  sleep/wake cycles and may exhibit some key lower brain functions, such as  spontaneous movement, opening and moving eyes, and grimacing. 
      Coma or PVS may  result from TBI, a nontraumatic insult to the brain (such as a vascular insult,  infection, or brain tumor), or a neurodegenerative or metabolic disorder.  
      Medically induced comas are not considered under <a href="#11_20" title="Section 11.20">11.20</a> and 
      should be considered under the section pertaining to the underlying reason the coma was medically induced and not under this section.</p>
      <p id="11_00S">S. <u>What are motor neuron disorders, other than ALS, and how do we evaluate them under <a href="#11_22" title="Section 11.22">11.22</a>?</u> 
      Motor neuron disorders such as progressive bulbar palsy, primary lateral sclerosis (PLS), and spinal muscular atrophy (SMA) are progressive neurological disorders that destroy the cells that control voluntary muscle activity, 
      such as walking, breathing, swallowing, and speaking.  We evaluate the effects of these disorders on motor functioning, bulbar and  neuromuscular functioning, oral communication, or limitations in physical and  mental functioning.</p>
      <p id="11_00T">T. <u>How do we consider symptoms of fatigue in these listings?</u> Fatigue is one of the most common and limiting symptoms of some neurological disorders, 
      such as multiple sclerosis, post-polio syndrome, and myasthenia gravis. These  disorders may result in physical fatigue (lack of muscle strength) or mental  fatigue (decreased awareness or attention). 
      When we evaluate your fatigue, we will consider the intensity, persistence, and effects of fatigue on your  functioning. 
      This may include information such as the clinical and laboratory data and other objective evidence concerning your neurological deficit, a description of fatigue considered characteristic of your disorder, 
      and information about your functioning. We consider the effects of physical fatigue  on your ability to stand up, balance, walk, 
      or perform fine and gross motor movements using the criteria described in <a href="#11_00D" title="Section 11.00D">11.00D</a>. 
      We consider the effects of physical and mental fatigue when we evaluate your physical and mental functioning described in <a href="#11_00G" title="Section 11.00, Subsection G">11.00G</a>.</p>
      <p id="11_00U">U.<u>How do we evaluate your neurological disorder when it does not meet one of these listings?</u></p>
      <ol type="1">
          <li id="11_00U1">If your neurological  disorder does not meet the criteria of any of these listings, we must also consider whether your impairment(s) meets the criteria of a listing in another body system. 
          If you have a severe medically determinable impairment(s) that does not meet a listing, we will determine whether your impairment(s) medically equals a listing. 
          See §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1526.htm" target="_blank" title="Code of Federal Regulations section 404.1526">404.1526</a> 
          and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a> of this chapter. </li>
          <li id="11_00U2">If your impairment(s)  does not meet or medically equal the criteria of a listing, you may or may not  have the residual functional capacity to perform your past relevant work or  adjust to other work that exists in significant numbers in the national  economy, which we determine at the fourth and, if necessary, the fifth steps of  the sequential evaluation process in §§ 404.1520 and 416.920 of this chapter. </li>
          <li id="11_00U3">We use the rules in  §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1594.htm" target="_blank" title="Code of Federal Regulations section 404.1594">404.1594</a> 
          and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994.htm" target="_blank" title="Code of Federal Regulations section 416.994">416.994</a> of this chapter, as appropriate, when we decide whether you continue to be disabled.</li>
      </ol>
      <p align="left" id="11_01"> <b>11.01 Category of Impairments, Neurological Disorders</b></p>
      <p align="left" id="11_02">
          <b>
              11.02
          </b><strong><u>Epilepsy</u>, documented by a detailed description of a typical seizure and characterized by A, B, C, or D:</strong>
      </p>
      <p align="left" id="11_02A">A. Generalized tonic-clonic seizures (see <a href="#11_00H1a" title="Section 11.00, Subsection H1a">11.00H1a</a>), 
      occurring at least once a month for at least 3 consecutive months (see <a href="#11_00H4" title="Section 11.00, Subsection H4">11.00H4</a>) despite adherence to prescribed treatment 
      (see <a href="#11_00C" title="Section 11.00, Subsection C">11.00C</a>). </p>
      <p align="left">OR</p>
      <p align="left" id="11_02B">B. Dyscognitive seizures (see <a href="#11_00H1b" title="Section 11.00, Subsection H1b">11.00H1b</a>), 
      occurring at least once a week for at least 3 consecutive months (see <a href="#11_00H4" title="Section 11.00H4">11.00H4</a>) despite adherence to prescribed treatment 
      (see <a href="#11_00C" title="Section 11.00, Subsection C">11.00C</a>).</p>
      <p id="11_02C">
          OR<br>
          C. Generalized tonic-clonic seizures
          (see <a href="#11_00H1a" title="Section 11.00, Subsection H1a">11.00H1a</a>),
          occurring at least once every 2 months for at least 4 consecutive months (see  <a href="#11_00H4" title="Section 11.00, Subsection H4">11.00H4</a>)
          despite adherence to prescribed treatment (see  <a href="#11_00C" title="Section 11.00, Subsection C">11.00C</a>); and a marked limitation in one of the following:
      </p>
      <ol type="1">
          <li id="11_02C1">Physical functioning  (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>); or</li>
          <li id="11_02C2">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_02C3">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_02C4">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_02C5">Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p id="11_02D">
          OR<br>
          D. Dyscognitive seizures (see <a href="#11_00H1b" title="Section 11.00, Subsection H1b">11.00H1b</a>), 
          occurring at least once every 2 weeks for at least 3  consecutive months (see <a href="#11_00H4" title="Section 11.00, Subsection H4">11.00H4</a>) despite adherence to prescribed treatment 
          (see <a href="#11_00C" title="Section 11.00, Subsection C">11.00C</a>); and a marked limitation in one of the following:
</p>
      <ol type="1">
          <li id="11_02D1">Physical functioning (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>); or</li>
          <li id="11_02D2">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_02D3">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_02D4">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_02D5">Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_03">
          <b>
              11.03 [Reserved]
          </b>
      </p>
      <p align="left" id="11_04">
          <b>
              11.04 <strong><u>Vascular insult to the brain</u>, characterized by A, B, or C:</strong>
          </b>
      </p>
      <p id="11_04A">
          A. Sensory or motor aphasia resulting in ineffective speech or communication (see <a href="#11_00E1" title="Section 11.00, Subsection E1">11.00E1</a>) persisting for at least 3 consecutive months after the insult.<br>
</p>
      <p>OR</p>
      <p id="11_04B">B. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, 
      balance while standing or walking, or use the upper extremities, persisting for at least 3 consecutive months after the insult. </p>
      <p>OR</p>
      <p id="11_04C">C. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning 
      (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>) and in one of the following areas of mental functioning, both persisting for at least 3 consecutive months after the insult:</p>
      <ol type="1">
          <li id="11_04C1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_04C2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_04C3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_04C4">Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_05">
          <b>
              11.05<strong><u> Benign brain tumors</u>, characterized by A or B: </strong>
          </b>
          <br>
      </p>
      <p id="11_05A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up  from a seated position, balance while standing or walking, or use the upper  extremities.</p>
      <p>OR</p>
      <p id="11_05B">B. Marked  limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning 
      (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of the following:</p>
      <ol type="1">
          <li id="11_05B1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_05B2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_05B3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_05B4">Adapting or managing  oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_06">
          <b>
              11.06 <strong><u>Parkinsonian syndrome</u></strong>
          </b>, characterized by A or B despite adherence to prescribed treatment for at least 3 consecutive  months (see <a href="#11_00C" title="Section 11.00, Subsection C">11.00C</a>):
</p>
      <p id="11_06A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.</p>
      <p>OR</p>
      <p id="11_06B">B. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning 
      (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of  the following:</p>
      <ol type="1">
          <li id="11_06B1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_06B2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_06B3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_06B4">Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_07">
          <b>
              11.07
          </b><strong><u>Cerebral palsy</u></strong>, characterized by A, B, or C:
      </p>
      <p id="11_07A">
          A. Disorganization of motor function in two extremities (see  <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>),
          resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.
      </p>
      <p>OR</p>
      <p id="11_07B">
          B. Marked limitation (see  <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning
          (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of the following:
      </p>
      <ol type="1">
          <li id="11_07B1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_07B2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_07B3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_07B4">Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p>OR</p>
      <p id="11_07C">C. Significant interference in communication due to speech, hearing, or visual deficit (see <a href="#11_00E2" title="Section 11.00, Subsection E2">11.00E2</a>). </p>
      <p align="left" id="11_08">
          <b>
          11.08
          </b><strong><u>Spinal cord disorders</u></strong>, characterized by A, B, or C:
      </p>
      <p id="11_08A">A. Complete loss of function, as described in <a href="#11_00M2" title="Section 11.00, Subsection M2">11.00M2</a>, 
      persisting for 3 consecutive months after the disorder (see <a href="#11_00M4" title="Section 11.00, Subsection M4">11.00M4</a>).</p>
      <p>OR</p>
      <p id="11_08B">B. Disorganization  of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, 
      or use the upper extremities persisting for 3 consecutive months after the disorder (see <a href="#11_00M4" title="Section 11.00, Subsection M4">11.00M4</a>).</p>
      <p>OR</p>
      <p id="11_08C">C. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) 
      in physical functioning (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>) and in one of the following areas of mental functioning, 
      both persisting for 3 consecutive months after the disorder (see <a href="#11_00M4" title="Section 11.00, Subsection M4">11.00M4</a>):</p>
      <ol type="1">
          <li id="11_08C1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_08C2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_08C3">
              Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or
</li>
          <li id="11_08C4">Adapting or managing  oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_09">
          <b>
              11.09
          </b><strong><u>Multiple sclerosis</u></strong>, characterized by A or B:
      </p>
      <p id="11_09A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>),  
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities. </p>
      <p>OR</p>
      <p id="11_09B">B. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), 
      and in one of  the following:</p>
      <ol type="1">
          <li id="11_09B1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_09B2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_09B3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_09B4">Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_10">
          <b>
              11.10 <strong><u>Amyotrophic lateral sclerosis (ALS)</u></strong> established by clinical and laboratory findings (see <a href="#11_00O" title="Section 11.00, Subsection O">11.00O</a>).
</b>
      </p>
      <p align="left" id="11_11">
          <b>
              11.11
          </b><strong><u>Post-polio syndrome</u></strong>, characterized by A, B, C, or D:
      </p>
      <p id="11_11A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.</p>
      <p>OR</p>
      <p id="11_11B">B. Unintelligible speech (see <a href="#11_00E3" title="Section 11.00, Subsection E3">11.00E3</a>).</p>
      <p>OR</p>
      <p id="11_11C">C. Bulbar and neuromuscular dysfunction (see <a href="#11_00F" title="Section 11.00, Subsection F">11.00F</a>), resulting in:</p>
      <ol type="1">
          <li id="11_11C1">Acute respiratory failure requiring mechanical ventilation; or</li>
          <li id="11_11C2">Need for supplemental enteral nutrition via a gastrostomy or parenteral nutrition via a central venous catheter.</li>
      </ol>
      <p>OR</p>
      <p id="11_11D">D. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of  the following:</p>
      <ol type="1">
          <li id="11_11D1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_11D2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_11D3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_11D4">Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_12">
          <b>
              11.12
          </b><strong><u>Myasthenia gravis</u></strong>, characterized by A, B, or C despite adherence  to prescribed treatment for at least 3 months (see <a href="#11_00C" title="Section 11.00, Subsection C">11.00C</a>):
</p>
      <p id="11_12A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.</p>
      <p>OR</p>
      <p id="11_12B">B. Bulbar and neuromuscular dysfunction (see <a href="#11_00F" title="Section 11.00, Subsection F">11.00F</a>), resulting in:</p>
      <ol type="1">
          <li id="11_12B1">One myasthenic crisis requiring mechanical ventilation; or</li>
          <li id="11_12B2">Need for supplemental enteral nutrition via a gastrostomy or parenteral nutrition via a central venous catheter.</li>
      </ol>
      <p>OR</p>
      <p id="11_12C">C. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning 
      (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of  the following:</p>
      <ol type="1">
          <li id="11_12C1">Understanding,  remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_12C2">Interacting with  others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_12C3">Concentrating,  persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_12C4">
              Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>).
</li>
      </ol>
      <p align="left" id="11_13">
          <b>
              11.13
          </b><strong><u>Muscular dystrophy</u></strong>, characterized by A or B:
      </p>
      <p id="11_13A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up  from a seated position, balance while standing or walking, or use the upper extremities.</p>
      <p>OR</p>
      <p id="11_13B">B. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning 
      (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of the following:</p>
      <ol type="1">
          <li id="11_13B1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_13B2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_13B3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_13B4">Adapting or managing  oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_14">
          <b>
              11.14
          </b><strong><u>Peripheral neuropathy</u></strong>, characterized by A or B:
      </p>
      <p id="11_14A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.</p>
      <p>OR</p>
      <p id="11_14B">B. Marked  limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning 
      (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of the following:</p>
      <ol type="1">
          <li id="11_14B1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_14B2">
              Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or
</li>
          <li id="11_14B3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_14B4">Adapting or managing oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_15">
          <b>
              11.15
          </b> [Reserved]
      </p>
      <p align="left" id="11_16">
          <b>
              11.16
          </b>[Reserved]
      </p>
      <p align="left" id="11_17">
          <b>
              11.17
          </b><strong><u>Neurodegenerative disorders of the central nervous system, such as Huntington’s disease, Friedreich’s ataxia, and spinocerebellar degeneration</u></strong>, characterized by A or B:
      </p>
      <p id="11_17A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, or use the upper  extremities.</p>
      <p>OR</p>
      <p id="11_17B">B. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of the following: </p>
      <ol type="1">
          <li id="11_17B1">Understanding,  remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_17B2">Interacting with  others (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(ii)</a>); or</li>
          <li id="11_17B3">Concentrating,  persisting, or maintaining pace (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(iii)</a>); or</li>
          <li id="11_17B4">
              Adapting or managing oneself (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(iv)</a>).
</li>
      </ol>
      <p align="left" id="11_18">
          <b>
              11.18
          </b><strong><u>Traumatic brain injury</u></strong>, characterized by A or B:
      </p>
      <p id="11_18A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>),
    resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up  from a seated position, balance while standing or walking, or use the upper extremities, 
      persisting for at least 3 consecutive months after the injury.
</p>
      <p>OR</p>
      <p id="11_18B">B. Marked  limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning 
      (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of  the following areas of mental functioning, persisting for at least 3 consecutive months after the injury:</p>
      <ol type="1">
          <li id="11_18B1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_18B2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_18B3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_18B4">Adapting or managing  oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>
      <p align="left" id="11_19">
          <b>
              11.19
          </b>[Reserved]
      </p>
      <p align="left" id="11_20"><b>11.20 </b><strong><u>Coma or persistent vegetative state</u>, persisting for at least 1 month</strong>.</p>
      <p align="left" id="11_21"><b>11.21 </b>[Reserved]</p>
      <p align="left" id="11_22"><b>11.22 </b><strong><u>Motor neuron disorders other than ALS</u></strong>, characterized by A, B, or C:</p>
      <p id="11_22A">A. Disorganization of motor function in two extremities (see <a href="#11_00D1" title="Section 11.00, Subsection D1">11.00D1</a>), 
      resulting in an extreme limitation (see <a href="#11_00D2" title="Section 11.00, Subsection D2">11.00D2</a>) in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.</p>
      <p>OR</p>
      <p id="11_22B">B. Bulbar and neuromuscular dysfunction (see <a href="#11_00F" title="Section 11.00, Subsection F">11.00F</a>), resulting in:</p>
      <ol type="1">
          <li id="11_22B1">Acute respiratory failure requiring invasive mechanical ventilation; or</li>
          <li id="11_22B2">Need for supplemental enteral nutrition via a gastrostomy or parenteral nutrition via a central venous catheter.</li>
      </ol>
      <p id="11_22C">C. Marked limitation (see <a href="#11_00G2" title="Section 11.00, Subsection G2">11.00G2</a>) in physical functioning (see <a href="#11_00G3a" title="Section 11.00, Subsection G3a">11.00G3a</a>), and in one of the following:</p>
      <ol type="1">
          <li id="11_22C1">Understanding, remembering, or applying information (see <a href="#11_00G3bi" title="Section 11.00, Subsection G3bi">11.00G3b(i)</a>); or</li>
          <li id="11_22C2">Interacting with others (see <a href="#11_00G3bii" title="Section 11.00, Subsection G3bii">11.00G3b(ii)</a>); or</li>
          <li id="11_22C3">Concentrating, persisting, or maintaining pace (see <a href="#11_00G3biii" title="Section 11.00, Subsection G3biii">11.00G3b(iii)</a>); or</li>
          <li id="11_22C4">Adapting or managing  oneself (see <a href="#11_00G3biv" title="Section 11.00, Subsection G3biv">11.00G3b(iv)</a>). </li>
      </ol>

 </article><!-- END SECOND INNER COLUMN -->
 
 </div><!-- END GRID-->

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt" href="#" title="Back to Top"></a>


</body></html>